<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/css" media="screen" href="http://feeds.feedburner.com/~d/styles/itemcontent.css"?><rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0" version="2.0">
<channel>
	<title>Comments for Pharma's Cutting Edge</title>
	
	<link>http://www.pharmaweblog.com</link>
	<description>Pharmaceutical and biotech science and business</description>
	<pubDate>Tue, 06 Jan 2009 15:33:20 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6</generator>
		<image><link>http://www.feedburner.com</link><url>http://www.feedburner.com/fb/images/pub/fb_pwrd.gif</url><title>This Feed Powered by FeedBurner.com</title></image><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" href="http://blog.crownstoneinsights.com/atom.xml" type="application/rss+xml" /><feedburner:browserFriendly>This is an XML content feed. It is intended to be viewed in a newsreader or syndicated to another site, subject to copyright and fair use.</feedburner:browserFriendly><item>
		<title>Comment on At the dawn of active immunotherapy for cancer by Promising drug tech in 2009 | Pharma's Cutting Edge</title>
		<link>http://www.pharmaweblog.com/2007/04/01/dawn-active-immunotherapy/#comment-219</link>
		<dc:creator>Promising drug tech in 2009 | Pharma's Cutting Edge</dc:creator>
		<pubDate>Tue, 06 Jan 2009 14:37:39 +0000</pubDate>
		<guid isPermaLink="false">http://pharmaweblog.com/blog/2007/04/01/dawn-active-immunotherapy/#comment-219</guid>
		
		<content:encoded><![CDATA[[...] (Provenge), Dendreon, active immunotherapy targeting prostatic acid phosphatase, advanced [...]<br/>
<br/>
This is a content summary only. Visit my blog at http://www.pharmaweblog.com for full content, links and more!<div class="feedflare">
<a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?a=hOyqCy.P"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?i=hOyqCy.P" border="0"></img></a> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?a=4DgxlA.P"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?i=4DgxlA.P" border="0"></img></a> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?a=v281xM.p"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?i=v281xM.p" border="0"></img></a> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?a=GoDhms.P"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?i=GoDhms.P" border="0"></img></a>
</div>]]></content:encoded>
	</item>
	<item>
		<title>Comment on Round-up of (unethical?) osteoporosis studies from ASBMR 2008 by Promising drug tech in 2009 | Pharma's Cutting Edge</title>
		<link>http://www.pharmaweblog.com/2008/09/18/round-up-of-unethical-osteoporosis-studies-from-asbmr-2008/#comment-215</link>
		<dc:creator>Promising drug tech in 2009 | Pharma's Cutting Edge</dc:creator>
		<pubDate>Fri, 02 Jan 2009 18:10:51 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmaweblog.com/?p=506#comment-215</guid>
		
		<content:encoded><![CDATA[[...] Denosumab, Amgen, human RANKL MAb, postmenopausal osteoporosis and osteoporosis in men [...]<br/>
<br/>
This is a content summary only. Visit my blog at http://www.pharmaweblog.com for full content, links and more!<div class="feedflare">
<a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?a=8OCvX8.P"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?i=8OCvX8.P" border="0"></img></a> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?a=o5W4yU.P"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?i=o5W4yU.P" border="0"></img></a> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?a=g8DdNn.p"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?i=g8DdNn.p" border="0"></img></a> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?a=zaJ8Ir.P"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?i=zaJ8Ir.P" border="0"></img></a>
</div>]]></content:encoded>
	</item>
	<item>
		<title>Comment on Top drug innovations: 2008 edition by Promising drug tech in 2009 | Pharma's Cutting Edge</title>
		<link>http://www.pharmaweblog.com/2008/12/16/top-drug-innovations-2008-edition/#comment-214</link>
		<dc:creator>Promising drug tech in 2009 | Pharma's Cutting Edge</dc:creator>
		<pubDate>Fri, 02 Jan 2009 18:03:54 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmaweblog.com/?p=609#comment-214</guid>
		
		<content:encoded><![CDATA[[...]                       « Top drug innovations: 2008 edition [...]<br/>
<br/>
This is a content summary only. Visit my blog at http://www.pharmaweblog.com for full content, links and more!<div class="feedflare">
<a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?a=KPmn8m.P"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?i=KPmn8m.P" border="0"></img></a> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?a=Xo0q3P.P"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?i=Xo0q3P.P" border="0"></img></a> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?a=Xzuc2L.p"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?i=Xzuc2L.p" border="0"></img></a> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?a=SKlodv.P"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgeComments?i=SKlodv.P" border="0"></img></a>
</div>]]></content:encoded>
	</item>
<feedburner:awareness>http://api.feedburner.com/awareness/1.0/GetFeedData?uri=PharmasCuttingEdgeComments</feedburner:awareness></channel>
</rss><!-- Dynamic Page Served (once) in 0.281 seconds -->
